RNAi therapeutics firm, Alnylam Pharmaceuticals in partnership with Massachusetts Institute of Technology (MIT) has published a new paper in the Proceedings of the National Academy of Sciences on the development of core-shell nanoparticles for delivering RNAi therapeutics systemically.
High-throughput polymer synthesis strategy is utilized for the production of core-shell nanoparticles, which was then filtered for intracellular delivery purposes such as siRNA delivery. The research findings in the paper can be used for the production of unique nanoparticles with optimal physical and chemical properties for efficient delivery of RNAi therapeutics.
During the study, the researchers assessed the ability of more than 1,500 chemically different nanoparticles in order to deliver drugs based on accurate control over architecture, chemical composition and particle size. As per the results, the chemical and physical properties of nanoparticles could control their use in the nanotherapeutics field and their specific chemical properties would allow them to be used for polymer-based delivery. By controlling and modifying the chemical properties of the shell and core of nanoparticles, they can be utilized in numerous drug delivery applications.
According to Kevin Fitzgerald, who serves as Alnylam’s Senior Director of Research, in the current research work, core-shell nanoparticles were generated utilizing combinatorial methods to discover unique materials for siRNA delivery. These results enhance the company’s systemic delivery platform to obtain a wide range of RNAi therapeutic applications, he added.
Dan Anderson of the David H. Koch Institute for Integrative Research at MIT stated that the new findings on core-shell nanoparticles focus non-lipid methods for siRNA delivery with room for further improvement.